Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%

On Monday, Novo Nordisk A/S (NYSE:NVO) released the headline results from the SOUL Phase 3 cardiovascular outcomes trial.

Last year, Novo Nordisk’s subcutaneous once-weekly (injectable) semaglutide 2.4 mg, available as Wegovy, showed a 20% reduction in MACE compared to placebo. 

The SOUL trial compared oral semaglutide to placebo as an adjunct to the standard of care to prevent major adverse cardiovascular events (MACE), such as cardiac arrest, stroke, heart failure, or cardiovascular death.

The SOUL trial was initiated in 2019 and enrolled 9,650 people with type 2 diabetes and established cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

Also Read: Novo Nordisk’s Weight Loss ...